4511

Epi-Ending- Novel Dual-Specificity Anti-Cancer Epigenetic Drugs

Ben-Sasson Shmuel, HUJI, School of Medicine - IMRIC, Developmental Biology and Cancer Research
Tsvelikhovsky Dmitry, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research
Additional information may be provided upon request

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
+972-2-6586608